drugset / Trial / NCT04229225

A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee

NCT04229225 ↗

Phase 1 Completed 35 enrolled Unity Biotechnology, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A study to assess safety, tolerability and clinical effects of single and repeat dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).

Timeline

Start
2020-01-23
Primary completion
2020-09-18
Completion
2020-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject UBX0101 Unknown 4 mg Other
Subject UBX0101 Unknown 8 mg Other

Indications